A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
A phase 3 trial of 9MW2821 in cervical cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
Overview
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT06692166 by Mabwell (Shanghai) Bioscience Co., Ltd., with 420 participants planned, started 2024-09-10 and due to reach its primary completion in 2027-12-09. Interventions recorded: 9MW2821 and Chemotherapy.
Similar pages
not linked directly; found by shared links- TrialPRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialA Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Shares Cervical cancer and the tag pipeline.
- TrialStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Shares Cervical cancer and the tag pipeline.
- TrialA Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
Shares Cervical cancer and the tag pipeline.
- TrialAutologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialImmunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
Shares Cervical cancer and the tag pipeline.
- TrialCamrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialStudy of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Shares Cervical cancer and the tag pipeline.